Nula Therapeutics, a biotechnology company developing a new class of medicines that target the nuclear envelope to treat chronic disease, neurodegeneration, cancer, and age-related conditions, has raised funding alongside a major non-dilutive public award as it advances its platform toward early therapeutic development.

The company’s most significant disclosed financing is an up to $20 million award from the U.S. government’s Advanced Research Projects Agency for Health, known as ARPA-H, which is designed to support high-risk, high-reward biomedical innovation. The funding will help accelerate Nula’s efforts to develop small-molecule therapies that correct dysfunction in the nuclear envelope, a structural component of the cell nucleus increasingly recognized for its role in regulating gene expression and cellular aging.

The award provides Nula Therapeutics with long-term support to advance its research platform, which focuses on modulating how the nuclear envelope organizes genetic material and controls which genes are turned on or off in response to cellular conditions. The company aims to translate this mechanism into targeted therapies that could address diseases driven by disrupted gene regulation.

In addition to ARPA-H support, Nula Therapeutics has attracted interest from early-stage life sciences investors and biotech-focused research collaborators, reflecting growing attention to nuclear architecture as a therapeutic target. While the company has not publicly disclosed a traditional venture capital-led seed or Series A round in detail, its funding structure is currently anchored by public innovation funding and translational research support.

Nula was founded by a team of scientists and biotech entrepreneurs focused on bridging fundamental cell biology with drug discovery. The company’s leadership includes researchers with experience in molecular biology, structural biology, and translational medicine, and its scientific foundation builds on recent advances in understanding how spatial organization within the nucleus influences disease progression.

The startup’s core platform is built around the concept that proximity to the nuclear envelope influences gene expression programs, and that misregulation of this spatial architecture contributes to diseases such as metabolic disorders, cancer, and neurodegeneration. By designing small molecules that restore or alter these interactions, Nula aims to reprogram diseased cellular states rather than simply treating downstream symptoms.

Unlike conventional drug discovery approaches that target individual proteins or signaling pathways, Nula’s method focuses on the physical organization of chromatin and nuclear structure. This positions the company within a growing wave of biotechnology firms exploring epigenetic and spatial biology as next-generation therapeutic strategies.

The ARPA-H funding will be used to advance proof-of-concept programs, expand computational and experimental modeling capabilities, and accelerate preclinical validation of candidate molecules. The company is expected to use the capital to refine its nuclear envelope-targeting platform and identify disease-specific pathways that can be modulated with small-molecule drugs.

Investor and public-sector interest in Nula reflects broader momentum in aging biology, epigenetics, and next-generation drug discovery platforms. Agencies like ARPA-H have increasingly prioritized funding for transformative approaches that move beyond traditional target-based drug development.

With its funding support in place, Nula Therapeutics is positioning itself at the frontier of nuclear biology-based medicine, aiming to unlock a new category of therapeutics that address the underlying cellular architecture of disease rather than its symptoms alone.

Related Articles